Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Mark A. Luttmann"'
Autor:
Ruth Tal-Singer PhD, Bruce E Miller PhD, Jean M Rommes PhD, Mark A Luttmann BS, Christophe Demaison PhD, M Bradley Drummond MD, Cara B Pasquale MPH
Publikováno v:
Journal of Patient Experience, Vol 10 (2023)
Patient-centric drug development is crucial to creating treatments that address unmet patient needs but is often ignored. The COPD Foundation's COPD360Net ® includes a multistakeholder approach for operationalizing patient-centric development of tre
Externí odkaz:
https://doaj.org/article/94bac05ec2e941a4bb1026bb469d5d9c
Autor:
M. Teresa Pulido-Rios, Mathai Mammen, TaeWeon Lee, James J. Foley, Sharath S. Hegde, Gerald E. Hunsberger, Jeffrey R. Jasper, Mark A. Luttmann, Tod Steinfeld, Yuhua Ji
Publikováno v:
Pharmacology Research & Perspectives
Revefenacin (TD‐4208) is a novel, long‐acting, and lung‐selective muscarinic cholinergic receptor (mAChR) antagonist in development as a nebulized inhalation solution for the treatment of chronic obstructive pulmonary disease (COPD) patients. T
Autor:
Henry M. Sarau, Sandra Umbrecht, Widdowson Katherine L, Palovich Michael R, Michael Salmon, Haibo Xie, Hongxing Yan, Jakob Busch-Petersen, Mark A. Luttmann, James J. Foley, Brian Peck, Jeremy Dufour, Zehong Wan, Gerald E. Hunsberger, Philip S. Landis, Dramane I. Laine, Alicia M. Bacon, Miriam Burman, Edward F. Webb, Roderick S. Davis, Dulcie B. Schmidt
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 22:3366-3369
A novel series of N-substituted tropane derivatives was characterized as potent muscarinic acetylcholine receptor antagonists (mAChRs). Kinetic washout studies showed that the N-endosubstituted analog 24 displayed much slower reversibility at mAChRs
Autor:
Robert J. Slack, David A. Hall, Mark A. Luttmann, Christopher Browning, Alison J. Ford, Linda J. Russell, HE Connor, KA Saunders, Simon Teanby Hodgson, Kenneth L. Clark
Publikováno v:
British Journal of Pharmacology. 164:1627-1641
BACKGROUND AND PURPOSE Preclinical pharmacological characterization of GSK1004723, a novel, dual histamine H1 and H3 receptor antagonist. EXPERIMENTAL APPROACH GSK1004723 was characterized in vitro and in vivo using methods that included radioligand
Autor:
Widdowson Katherine L, Douglas W. P. Hay, Keith W. Ward, Chongjie Zhu, Mary S. Barnette, Henry M. Sarau, Mark A. Luttmann, Larry J. Jolivette, James F. Callahan, Hongxing Yan, Zehong Wan, Jeffrey K. Kerns, Qi Jin
Publikováno v:
Synthetic Communications. 35:3105-3112
A novel and highly convergent synthesis leading to 2‐phenyl‐quinolines has been developed. As demonstrated in the preparation of 6‐fluoro‐3‐(3‐oxo‐piperazin‐1‐ylmethyl)‐2‐phenyl‐quinoline‐4‐carboxylic acid [(S)‐1‐cyclo
Autor:
Douglas W. P. Hay, Raveglia Luca Francesco, Don E. Griswold, Brian Bush, Punam Sandhu, Henry M. Sarau, Dulcie B. Schmidt, Giuseppe Giardina, James J. Foley, Mario Grugni, Jeffrey J. Legos, Lenox D. Martin, Dave Lundberg, Charles J. Kotzer, David J. Kilian, William Potts, Frank C. Barone, Mark A. Luttmann, David C. Underwood
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 300:314-323
In this report the in vitro and in vivo pharmacological and pharmacokinetic profile of (-)-(S)-N-(alpha-ethylbenzyl)-3-(carboxymethoxy)-2-phenylquinoline-4-carboxamide (SB 235375), a low central nervous system (CNS)-penetrant, human neurokinin-3 (NK-
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 349(1)
Prior studies have demonstrated that the ion channel transient receptor potential vanilloid 4 (TRPV4) is functionally expressed in airway smooth muscle cells and that TRPV4 single nucleotide polymorphisms are associated with airflow obstruction in pa
Autor:
Douglas W. P. Hay, Paul Rigby, Rodney M Moesker, Roy G. Goldie, Mark A. Luttmann, Glenn J. Self, Zhaohui Ao, Stephen A. Douglas
Publikováno v:
British Journal of Pharmacology. 132:1905-1915
The role of endothelin B (ETB) receptors in mediating ET ligand-induced contractions in mouse trachea was examined in ETB receptor knockout animals. Autoradiographic binding studies, using [125I]-ET-1, confirmed the presence of ETA receptors in trach
Autor:
Giorgio Pifferi, Luca F. Raveglia, Giuseppe Giardina, Douglas W. P. Hay, Davide Graziani, Renzo Mena, Marco Artico, Mark A. Luttmann, Mauro Vitali
Publikováno v:
European Journal of Medicinal Chemistry. 34:825-835
To rapidly gain information on structure-activity relationship (SAR) requirements of the human neurokinin 3 (hNK-3) receptor antagonist SR 142801, an indexed combinatorial library was synthesised in solution and screened on the hNK-3 receptor. SAR co
Autor:
Douglas W. P. Hay, Elaine M. L. Tan, Mark A. Luttmann, Vincenzo Ciocca, Thomas B. Leonard, Reynold A. Panettieri
Publikováno v:
American Journal of Respiratory Cell and Molecular Biology. 19:453-461
The cysteinyl leukotrienes (CysLTs) mimic many of the features of asthma and are implicated in its pathophysiology. Little, however, is known about the effects of the CysLTs on airways remodeling. In this study the effects of leukotriene D4 (LTD4) on